Your browser doesn't support javascript.
loading
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Gleixner, Karoline V; Schneeweiss, Mathias; Eisenwort, Gregor; Berger, Daniela; Herrmann, Harald; Blatt, Katharina; Greiner, Georg; Byrgazov, Konstantin; Hoermann, Gregor; Konopleva, Marina; Waliul, Islam; Cumaraswamy, Abbarna A; Gunning, Patrick T; Maeda, Hiroshi; Moriggl, Richard; Deininger, Michael; Lion, Thomas; Andreeff, Michael; Valent, Peter.
Afiliación
  • Gleixner KV; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria karoline.gleixner@meduniwien.ac.at.
  • Schneeweiss M; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.
  • Eisenwort G; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.
  • Berger D; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.
  • Herrmann H; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria.
  • Blatt K; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.
  • Greiner G; Department of Radiation Therapy, Medical University of Vienna, Austria.
  • Byrgazov K; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria.
  • Hoermann G; Department of Laboratory Medicine, Medical University of Vienna, Austria.
  • Konopleva M; Children's Cancer Research Institute (CCRI), Vienna, Austria.
  • Waliul I; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.
  • Cumaraswamy AA; Department of Laboratory Medicine, Medical University of Vienna, Austria.
  • Gunning PT; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • Maeda H; Institute of Drug Delivery Sciences, Sojo University, Kumamoto and BioDynamics Research Laboratory, Kumamoto, Japan.
  • Moriggl R; Department of Chemistry, University of Toronto, Canada.
  • Deininger M; Department of Chemistry, University of Toronto, Canada.
  • Lion T; Institute of Drug Delivery Sciences, Sojo University, Kumamoto and BioDynamics Research Laboratory, Kumamoto, Japan.
  • Andreeff M; Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria.
  • Valent P; Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria.
Haematologica ; 102(9): 1519-1529, 2017 09.
Article en En | MEDLINE | ID: mdl-28596283
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Células Madre Neoplásicas / Leucemia Mielógena Crónica BCR-ABL Positiva / Proteínas de Fusión bcr-abl / Sistemas de Liberación de Medicamentos / Resistencia a Antineoplásicos / Inhibidores de Proteínas Quinasas / Factor de Transcripción STAT3 / Factor de Transcripción STAT5 Límite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2017 Tipo del documento: Article País de afiliación: Austria
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Células Madre Neoplásicas / Leucemia Mielógena Crónica BCR-ABL Positiva / Proteínas de Fusión bcr-abl / Sistemas de Liberación de Medicamentos / Resistencia a Antineoplásicos / Inhibidores de Proteínas Quinasas / Factor de Transcripción STAT3 / Factor de Transcripción STAT5 Límite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2017 Tipo del documento: Article País de afiliación: Austria